Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum

Genexine has reached a critical point in developing its immuno-oncology pipeline, firming up a $548m-plus licensing out pact for an asset with the Shanghai-based I-Mab Biopharma. The South Korean firm expects the deal to serve as a yardstick of ‘value determination’ in its future global transactions.

Flags

Genexine Inc. has licensed out its proprietary long-acting immuno-oncology drug HyLeukin to I-MAB Biopharma for $548m plus sales royalties, marking the South Korean biotech company's first immuno-oncology deal.

HyLeukin, also known as GX-I7, is an immuno-oncology agent comprising an optimally engineered Interleukin-7 (IL-7) molecule based on Genexine’s proprietary...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip